Pathomechanism and Management of Stroke in COVID-19: Review of Immunopathogenesis, Coagulopathy, Endothelial Dysfunction, and Downregulation of ACE2
Open Access
- 1 January 2021
- journal article
- review article
- Published by XMLink in Journal of Clinical Neurology
- Vol. 17 (2) , 155-163
Abstract
Rahmawati PL, et al. J Clin Neurol. 2021 Apr;17(2):155-163. https://doi.org/10.3988/jcn.2021.17.2.155Keywords
This publication has 69 references indexed in Scilit:
- Angiotensin-Converting Enzyme 2: Central Regulator for Cardiovascular FunctionCurrent Hypertension Reports, 2010
- Angiotensin‐converting enzyme 2 in the brain: properties and future directionsJournal of Neurochemistry, 2008
- Neuroprotection by pravastatin in acute ischemic stroke in ratsBrain Research Reviews, 2008
- Inflammation, endothelium, and coagulation in sepsisJournal of Leukocyte Biology, 2007
- Downregulation of angiotensin converting enzyme II is associated with pacing‐induced sustained atrial fibrillationFEBS Letters, 2007
- Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular systemAmerican Journal of Physiology-Cell Physiology, 2007
- Advances in biochemical and functional roles of angiotensin-converting enzyme 2 and angiotensin-(1–7) in regulation of cardiovascular functionAmerican Journal of Physiology-Heart and Circulatory Physiology, 2005
- Bidirectional Relation Between Inflammation and CoagulationCirculation, 2004
- Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesisThe Journal of Pathology, 2004
- Mevastatin, an HMG-CoA Reductase Inhibitor, Reduces Stroke Damage and Upregulates Endothelial Nitric Oxide Synthase in MiceStroke, 2001